for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

55.70USD

Change

1.17(+2.15%)

Volume

3,965,546

Today's Range

55.37

 - 

56.43

52 Week Range

33.36

 - 

61.70

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
54.53
Open
55.86
Volume
3,965,546
3M AVG Volume
861.17
Today's High
56.43
Today's Low
55.37
52 Week High
61.70
52 Week Low
33.36
Shares Out (MIL)
5,612.87
Market Cap (MIL)
306,069.60
Forward P/E
12.89
Dividend (Yield %)
2.93

Next Event

Pfizer Inc at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual)

Latest Developments

More

Pfizer To Provide U.S. Government With Additional 10 Million Treatment Courses Of Its Covid-19 Oral Therapy

Pfizer And BionTech Receive FDA Authorization Of COVID-19 Vaccine Booster For Individuals 12 Years Of Age And Older

UK's MHRA Approves Oral COVID-19 Antiviral, Paxlovid

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Payal Sahni

Chief Human Resource Officer, Executive Vice President

Lidia Fonseca

Executive Vice President, Chief Technology Officer and Digital Officer

Rady A. Johnson

Executive Vice President, Chief Compliance, Quality and Risk Officer

Key Stats

2.35 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

53.6K

2019

51.8K

2020

41.9K

2021(E)

81.9K
EPS (USD)

2018

3.000

2019

2.950

2020

2.220

2021(E)

4.233
Price To Earnings (TTM)
16.43
Price To Sales (TTM)
4.41
Price To Book (MRQ)
4.04
Price To Cash Flow (TTM)
12.80
Total Debt To Equity (MRQ)
52.69
LT Debt To Equity (MRQ)
47.89
Return on Investment (TTM)
13.46
Return on Equity (TTM)
10.59

Latest News

Latest News

Factbox-Latest on the worldwide spread of the coronavirus

Britain and Israel are overhauling their COVID-19 testing policies as governments seek to ease the burden on laboratories and struggle with tight supplies of kits amid soaring infection rates fuelled by the Omicron variant.

Pfizer, BioNTech to develop shingles shot, after COVID-19 vaccine success

Pfizer Inc and Germany's BioNTech SE will develop an mRNA-based vaccine for viral infection shingles, collaborating for the third time after the success of their COVID-19 vaccine based on the same technology.

Israel reports very few myocarditis cases among 12-15 year olds after booster

Only two cases of myocarditis were reported in Israel among 44,000 youngsters aged 12 to 15 who received a third dose of the Pfizer/BioNtech vaccine, the Health Ministry said on Wednesday.

Ireland seeks to buy Merck, Pfizer, GSK COVID-19 antiviral drugs

Ireland's government agreed on Wednesday to fund the purchase of COVID-19 antiviral drugs from GlaxoSmithKline, Pfizer and Merck.

Israel reports very few myocarditis cases among 12-15 year olds after booster

Only two cases of myocarditis were reported in Israel among 44,000 youngsters aged 12 to 15 who received a third dose of the Pfizer/BioNtech vaccine, the Health Ministry said on Wednesday.

South Korea agrees to buy additional Pfizer COVID-19 pills

South Korea signed an agreement to buy additional courses of Pfizer Inc's antiviral COVID-19 pill Paxlovid to cover 400,000 people, the Korea Disease Control and Prevention Agency (KDCA) said on Wednesday.

Pfizer, BioNTech to jointly develop shingles vaccine

Pfizer Inc and Germany's BioNTech SE will collaborate to develop a potential mRNA-based vaccine for the prevention of viral infection shingles, the companies said on Wednesday. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shinjini Ganguli)

U.S. court revives lawsuit against Pfizer, others on Iraq terrorism funding claims

A U.S. appeals court on Tuesday revived a lawsuit against AstraZeneca Plc, Pfizer Inc and other companies over allegations their contracts with Iraq's health ministry helped fund terrorism that killed Americans during the war in Iraq.

Pfizer to supply U.S. with 10 million more courses of COVID-19 pills

The Biden administration doubled its order for Pfizer Inc's oral COVID-19 antiviral treatment, the company and the White House said on Tuesday, providing the government a total of 20 million courses as it fights a record surge in COVID-19 cases.

Brazilians favor COVID-19 vaccinating of children, oppose need for prescription - hearing

Brazil's Health Ministry said on Tuesday that most participants in a public hearing on vaccinating children aged 5 to 11 for COVID-19 disagreed with the need for a doctor's prescription, but it will still recommend it.

Pfizer to supply 10 mln additional courses of COVID-19 pill to U.S. govt

Pfizer Inc said on Tuesday the U.S. government has agreed to buy additional 10 million courses of its COVID-19 oral therapy, bringing the total amount of order by the government to 20 million courses. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli...

U.S. CDC recommends five-month gap for Pfizer COVID-19 booster dose

The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday recommended shortening the interval between Pfizer-BioNTech's second COVID-19 vaccine dose and the booster shot to five months from six.

U.S. CDC endorses five month gap for Pfizer's COVID-19 booster dose

The U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday it recommends the shortening of the interval between the second dose and booster shot of Pfizer-BioNTech from 6 months to 5 months.

Japan's Kishida lays out new contigency plan against Omicron risk

Japan will gear up efforts to deal with a possible surge in Omicron coronavirus cases and aim to deliver oral treatment using Pfizer Inc's drugs nationwide next month, Prime Minister Fumio Kishida said on Tuesday.

U.S. FDA authorizes Pfizer's COVID-19 booster for 12- to 15-year-olds

The U.S. Food and Drug Administration on Monday authorized the use of a third dose of the Pfizer and BioNTech COVID-19 vaccine for children ages 12 to 15, and narrowed the interval for booster shot eligibility to five months from six.

U.S. CDC panel to discuss Pfizer COVID-19 booster shot for 12- to 15-year olds

A U.S. Centers for Disease Control and Prevention advisory panel is set to meet on Wednesday to discuss the use of a booster dose of Pfizer and BioNTech's COVID-19 vaccine for children aged 12 to 15 years, according to the agency's website https://www.cdc.gov/vaccines/acip...

U.S. FDA clears Pfizer's COVID-19 booster shot for 12- to 15-year-olds

The U.S. Food and Drug Administration on Monday authorized the https://www.fda.gov/media/150386/download use of a third dose of the Pfizer and BioNTech COVID-19 vaccine for children aged between 12 and 15 years. (Reporting by Ankur Banerjee and Manas Mishra in Bengaluru)

UPDATE 1-Belgium agrees to buy 10,000 courses each of Pfizer, Merck COVID-19 pills

Belgium has agreed to buy 10,000 courses each of the COVID-19 antiviral oral treatments developed by Pfizer and Merck & CO, a spokesman for the health ministry told Reuters in an emailed statement on Monday.

Belgium to buy 10,000 courses each of Pfizer and Merck COVID-19 pills

Belgium will buy 10,000 courses each of the COVID-19 antiviral oral treatments developed by Pfizer and Merck & CO, a spokesman for the health ministry said in an emailed statement.

Israel to offer fourth COVID vaccine shot to over 60s, medical staff

Prime Minister Naftali Bennett said on Sunday that Israel would offer a fourth dose of COVID-19 vaccine to people over 60 and to medical staff as it faces a surge in Omicron variant infections.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up